Taflotan eye drops 15 μg/ml, 2.5 ml — Made in Finland — Free Delivery

Eye drops "Taflotan®" are used for the indications listed below.

Reduction of increased intraocular pressure in open-angle glaucoma and ocular hypertension in adults.

It is used as monotherapy for patients:

with insufficient response to treatment with first-line preparations;

with intolerance or contraindications to treatment with first-line preparations.

As an adjunct treatment in combination with beta blockers.

The active ingredient is tafluprost (1 ml of eye drops contains 15 mcg of tafluprost, 1 bottle (2.5 ml) of eye drops contains 37.5 mcg of tafluprost).

Excipients: benzalkonium chloride; glycerol; sodium dihydrogen phosphate, dihydrate; disodium edetate; polysorbate 80; sodium hydroxide or concentrated hydrochloric acid; water for injections.

Hypersensitivity to the active substance tafluprost or any of the excipients.

The recommended dose is one drop of the preparation into the conjunctival sac of the affected eye (s) 1 time per day in the evening.

It is not recommended to inject the preparation more often than once a day, since more frequent administration can reduce the effect of reducing intraglonal pressure.

To prevent potential contamination of the solution, patients should not touch their eyelids, surrounding areas or any other surfaces with the dropper tip of the vial.

To reduce the risk of darkening of the eyelid skin, patients should wipe excess solution from the skin. As with any other eye drops, after administration of the preparation, it is recommended to block the nasolacrimal passages or slightly cover the eyelids. This can reduce the systemic absorption of preparations that are administered by the intraocular route.

If the patient uses more than one topical ophthalmic preparation, the intervals between the administration of each agent should be at least 5 minutes.

The preparation should not be used by women of reproductive age who are not using appropriate contraception.

The preparation should not be used during pregnancy, unless absolutely necessary (in the absence of other treatment options).

It is not known whether tafluprost or its metabolites are excreted in breast milk. You should not use tafluprost while breastfeeding.

In rats, administration of tafluprost at doses up to 100 μg / kg / day did not affect the ability to mate and fertility.

The safety and efficacy of tafluprost in children (under the age of 18) have not been established. No data available.

Tafluprost does not affect the ability to drive vehicles and work with other mechanisms. As with any means for intraocular administration, if short-term blurred vision is observed after using the preparation, the patient should wait for clear vision before driving or operating other mechanisms.

Overdose in the case of intraocular administration is unlikely. In case of overdose, treatment is symptomatic.

During clinical trials, more than 1400 patients used tafluprost as monotherapy or as an adjunctive treatment to timolol 0.5%. The most common treatment-related adverse reaction was flushing. It occurred in about 13% of patients who participated in clinical trials of tafluprost in Europe and the United States. In most cases, hyperemia was mild and led to preparation withdrawal on average in only 0.4% of patients participating in the baseline studies.

Store in its original packaging at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life is 3 years.

Use within 4 weeks after opening the bottle.